A drug trial failure this spring has had no impact on the market for one of Bristol Myers Squibb’s most closely-watched new ...

By Michael Erman and Bhanvi Satija (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

Bristol Myers Squibb surpassed analyst expectations with a strong Q2, as notable brands Eliquis, Opdivo, and Revlimid drove ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Out of all of the special options we uncovered, 26 are puts, for a total amount of $1,771,839, and 16 are calls, for a total amount of $839,064. Taking into account the Volume and Open Interest on ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...